C4 Therapeutics Ptb Ratio Over Time
| CCCC Stock | USD 4.55 0.36 8.59% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out C4 Therapeutics Performance and C4 Therapeutics Correlation. CCCC |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share 0.522 | Quarterly Revenue Growth 0.387 | Return On Assets (0.21) | Return On Equity (0.46) |
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ptb Ratio Analysis
Compare C4 Therapeutics and related stocks such as Shattuck Labs, Eliem Therapeutics, and Prelude Therapeutics Ptb Ratio Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STTK | (26.2703) | (26.2703) | (26.2703) | (26.2703) | (26.2703) | (26.2703) | (26.2703) | (26.2703) | (26.2703) | (23.3805) | 7.0646 | 1.3161 | 0.5533 | 2.099 | 2.2 |
| PRLD | (37.0677) | (37.0677) | (37.0677) | (37.0677) | (37.0677) | (37.0677) | (37.0677) | (37.0677) | (37.0677) | (17.1806) | 14.7379 | 2.0729 | 1.464 | 1.087 | 1.14 |
| GLUE | (76.7186) | (76.7186) | (76.7186) | (76.7186) | (76.7186) | (76.7186) | (76.7186) | (76.7186) | (76.7186) | (76.7186) | (19.1261) | 2.7345 | 1.3242 | 1.62 | 1.7 |
| FHTX | (9.0567) | (9.0567) | (9.0567) | (9.0567) | (9.0567) | (9.0567) | (9.0567) | (9.0567) | (9.0567) | (7.5802) | 5.1014 | 8.7756 | 2.4 K | (3.5074) | (3.33) |
| RZLT | (6.9 K) | (6.9 K) | (6.9764) | 3.9989 | 4.5122 | 2.8238 | 5.472 | (6.3232) | 10.0438 | 3.631 | 4.1942 | 0.3932 | 0.8724 | 1.8331 | 1.92 |
| IPSC | (13.6257) | (13.6257) | (13.6257) | (13.6257) | (13.6257) | (13.6257) | (13.6257) | (13.6257) | (13.6257) | (13.6257) | (11.7623) | 2.2017 | 0.9787 | 1.0659 | 1.12 |
| EWTX | (87.6112) | (87.6112) | (87.6112) | (87.6112) | (87.6112) | (87.6112) | (87.6112) | (87.6112) | (87.6112) | (87.6112) | (44.1805) | 2.7566 | 1.3819 | 2.1865 | 2.3 |
| MLYS | (200) | (200) | (200) | (200) | (200) | (200) | (200) | (200) | (200) | (200) | (200) | (31.4157) | (14.4138) | 1.2905 | 1.36 |
| CGEM | (16.5831) | (16.5831) | (16.5831) | (16.5831) | (16.5831) | (16.5831) | (16.5831) | (16.5831) | (16.5831) | (31.9223) | (16.7637) | 1.6173 | 0.8906 | 0.9322 | 0.98 |
| ARVN | 11.9413 | 11.9413 | 11.9413 | 11.9413 | 11.9413 | 11.9413 | 11.9413 | 1.4 K | 0.886 | 5.9686 | 5.2279 | 5.2539 | 3.2218 | 3.4612 | 3.29 |
| NRIX | (8.3096) | (8.3096) | (8.3096) | (8.3096) | (8.3096) | (8.3096) | (8.3096) | (8.3096) | (12.7949) | 2.3013 | 3.6116 | 1.9831 | 1.6858 | 1.52 | 1.59 |
| KYMR | (43.0088) | (43.0088) | (43.0088) | (43.0088) | (43.0088) | (43.0088) | (43.0088) | (43.0088) | (43.0088) | (19.905) | 3.7891 | 6.6287 | 2.7464 | 3.7623 | 3.95 |
| RVMD | 233 | 233 | 233 | 233 | 233 | 233 | 233 | 233 | 10.9051 | 11.1786 | 5.5547 | 3.0412 | 2.8029 | 1.777 | 1.69 |
C4 Therapeutics and related stocks such as Shattuck Labs, Eliem Therapeutics, and Prelude Therapeutics Ptb Ratio description
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.My Equities
My Current Equities and Potential Positions
| C4 Therapeutics | CCCC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 4.55
Check out C4 Therapeutics Performance and C4 Therapeutics Correlation. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
C4 Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.